Compounded Sema Injectable denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied as Duplicate Therapy — and Why You Can Appeal

UHC's duplicate-therapy denial means the plan determined that compounded semaglutide injectable provides the same clinical effect as another drug already on your active claim record — most commonly a branded GLP-1 receptor agonist. UHC uses automated claims logic to flag overlapping therapeutic categories, so this denial can fire even when the two agents have meaningful clinical differences or when the overlapping claim is outdated or erroneous.

This is one of the more straightforward denial types to overturn because it often rests on an administrative data error rather than a clinical judgment.

## Your Federal Appeal Rights

Under ACA §2719 you may pursue independent external review after exhausting UHC's internal process. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review with access to every document and guideline the plan relied upon. The external-review window is generally open for approximately four months after a final internal denial. Request an expedited review if your condition makes delay medically risky — UHC must respond within 72 hours.

## The Concrete Appeal Process

1. Review the denial letter for exactly which drug UHC considers the duplicate. 2. Confirm with your pharmacy and prescriber whether that other medication is still active, was discontinued, or was never actually dispensed. 3. File a Level 1 internal appeal explaining why the two therapies are not truly duplicative (different mechanism, different indication, or the other claim is stale). 4. If unsuccessful, proceed to external IRO review, which is binding on UHC.

## Documentation to Gather

• Diagnosis confirmation — office notes and ICD codes for the condition being treated with compounded semaglutide.
• Medication reconciliation — a current, dated medication list from your prescriber confirming which agents are and are not active.
• Discontinuation records — if the drug UHC flagged as the duplicate was stopped, provide the chart note or pharmacy record showing the stop date and reason.
• Prescriber medical-necessity letter — should explain why compounded semaglutide is clinically distinct or necessary for this patient, and that no therapeutically equivalent agent is currently being used.
• Clinical differentiation note — if the prescriber believes the two agents are not interchangeable for this patient's specific clinical situation, that reasoning should be documented explicitly.

## Criteria-Mapping Structure

Request UHC's duplicate-therapy policy criteria in writing. Then address each point:

| UHC Duplicate-Therapy Criterion | Your Response with Chart Evidence | |---|---| | [Copy each criterion from UHC's policy exactly] | [Specific chart date, note, or medication list entry that refutes the duplication finding] |

If the denial is simply a data error — the other drug was never active or has been discontinued — a corrected claim or a short prescriber attestation may resolve it without a full appeal. Escalate to the formal appeal track only if UHC does not correct the record administratively.